HIMS

joe smith

@jobo333123Oct 31

@corleoneinvests All-in on one name is risky; I’d sanity-check $HIMS with @MarkLautr before liquidating anything.

Corleone Invests

@corleoneinvestsOct 31

I’m considering liquidating my portfolio and going all in on $HIMS… Is this a good idea? https://t.co/kGvqIMCC3b

Joshua E.Z.

@Sat_joshi163Oct 31

After the recent drawdown, $ENHA is now valued at just $129 million. Quick reminder: We went public at a valuation of 1 billion. $HIMS has a market capitalization of approximately $6.46 billion. That's a 50x difference in valuation. Of course, Hims & Hers is a much more

otium

@otium33Oct 31

super well made. expect/hope similar things from $hims on the app/software side eventually @AndrewDudum https://t.co/kv3TBimEW7

Alpha Owl

@AlphaOwlTradingOct 31

@arthritisfinger @RyFanaro Cant wait for $HIMS to explode

Nate

@robeyqiOct 31

$OSS -40% $RDDT -36% $RKLB -23% $DUOL -8% $HIMS -4% まぁ過去1ヶ月はあんまり気持ち良くないよな。勝ったのは $RBLX のみ。

Nate

@robeyqiOct 31

$HIMS がまた dis られているのか😂 https://t.co/NUIQmYAwLL

Arthritisfinger

@arthritisfingerOct 31

@RyFanaro @AlphaOwlTrading Triple digits is definitely my PT. Just like $HIMS

Javier Ballve

@jbm_1992Oct 31

$HIMS 5 years ago: hair loss, ED and skin. Today: weight loss, hormones, blood labs, its own peptide plant, and 9 acquisitions across the US, Canada, Europe and Australia. Where I think it goes: one $100/month membership for everything. → peptides for recovery, skin, sleep, https://t.co/ia6CR00m99 https://t.co/yU2bKY2SDu

Javier Ballve

@jbm_1992Oct 31

$HIMS management said they'd get 1-3 points of marketing leverage a year. They did 7 in 2025. Feb 2025: "1-3 points of marketing leverage per annum" → FY25 marketing 39% of sales, down 7 pts → Q2'26 at 34%, down another 5 pts YoY May 2026: "G&A will experience leverage" as https://t.co/H97UJ9EqJ3

Himtoshi Bonermoto

@0xBakutoOct 31

Never go soft. $HIMS robinhood:0x98096d17e191b3da1d5f99a6d7b3584351b11e18 https://t.co/yKITlTqbVk

The Right Move | Dan Right

@therightmovehqOct 31

@alc2022 I’m long $HIMS, but peptide pricing worries me. They’re charging roughly double some competitors. Growth looks great until margins get squeezed. Then the stock pays the price.

Javier Ballve

@jbm_1992Oct 31

$HIMS marketing went from 45% of sales to 35% in under 2 years. Meanwhile G&A doubled from 11% to 22%. Here's what's actually going on. Marketing % of sales: • Q3'24: 45.4% → Q2'26: 34.8% That's the leverage. G&A % of sales: • Reported: 11.1% → 22.0% • Adjusted: 10.9% → https://t.co/UTJcWEgNx1 https://t.co/iKPtOAqT7r

DIVINE💯

@BerrySmith70546Oct 31

$HIMS - 0xCceE82fE024c36fA15E1005edE3E9e4787e23D09 Scan ref v⁠u7t3е https://t.co/1SIc8RJb2o https://t.co/Qvo14Y0pyv

Argyros_Investor

@Argyros_MoneyOct 31

@alc2022 and $HIMS Revenue will grow 50% cagr for many years

Marzo

@MarzoIndustriesOct 31

AI applied to biology comes next. Easiest way to play it while offering high returns is $HIMS Base case is they grow at a 30% CAGR over the next decade. https://t.co/uYtobqTLXT

Spy Before You Buy

@Spybef0rey0ubuyOct 31

I'm hunting for beaten-down stocks with serious upside potential. 1. $IREN 2. $RKLB 3. $IONQ 4. $SOFI 5. $AAOI 6. $HIMS I'm looking for opportunity before the crowd catches on. High risk, high potential. NFA.

Juan Preciado

@preciado_juan01Oct 31

@madstreetbets $HIMS

YOUNG90

@Choi_MY90Oct 31

@CantoRobinHood $HIMS